Cargando…
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
While radium (Ra)-223 is among the multiple, known life-prolonging treatments in bone-predominant metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequencing has not been determined, particularly in the Asia-Pacific context. Hence, we aimed to compare treatment outcomes of...
Autores principales: | Chiang, Ping-Chia, Chiang, Po-Hui, Chen, I-Hsuan Alan, Chen, Yen-Ta, Wang, Hung-Jen, Cheng, Yuan-Tso, Kang, Chih-Hsiung, Chen, Chien-Hsu, Liu, Yi-Yang, Su, Yu-Li, Chen, Yen-Hao, Luo, Hao-Lun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901946/ https://www.ncbi.nlm.nih.gov/pubmed/36749250 http://dx.doi.org/10.1097/MD.0000000000032671 |
Ejemplares similares
-
The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis
por: Chang, Yin Lun, et al.
Publicado: (2023) -
Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review
por: Wahid, Sharjil, et al.
Publicado: (2017) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
por: Kim, Choung Soo, et al.
Publicado: (2017)